Evidence map›Paper›PMID 41068150›Full record

ArticleScientific reports2025

Patient-reported vision impairment in low luminance relates to visual function in age-related macular degeneration: A MACUSTAR study report.

Jan Henrik Terheyden, Charlotte Behning, Hannah M P Dunbar, Stephen Poor, Nadia Zakaria, Alison M Binns, Marlene Saßmannshausen, Sergio Leal, Matthias Schmid, Frank G Holz and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Macular degeneration collection.Scientific reports · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jan Henrik TerheydenDepartment of Ophthalmology, University Hospital Bonn, Bonn, Germany.
Charlotte BehningInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Hannah M P DunbarUCL Institute of Ophthalmology, University College London, London, UK.
Stephen PoorNovartis Pharma AG, Basel, Switzerland.
Nadia ZakariaNovartis Pharma AG, Basel, Switzerland.
Alison M BinnsDivision of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK.
Marlene SaßmannshausenDepartment of Ophthalmology, University Hospital Bonn, Bonn, Germany.
Sergio LealBayer AG, Berlin, Germany.
Matthias SchmidInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Frank G HolzDepartment of Ophthalmology, University Hospital Bonn, Bonn, Germany.
David P CrabbDivision of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK.
Ulrich F O LuhmannRoche Pharmaceutical Research and Early Development, Translational Medicine Ophthalmology, Roche Innovation Center Basel, Basel, Switzerland.
Robert P FingerDepartment of Ophthalmology, University Hospital Bonn, Bonn, Germany. robertpatrick.finger@umm.de.
MACUSTAR consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early stages of age-related macular degeneration (AMD) can lead to a number of visual function deficits, but the patient relevance of these deficits is largely unknown. We therefore investigated how bilateral visual function domains affected by age-related macular degeneration (AMD) are associated with patient-reports. Using data from the cross-sectional part of the MACUSTAR study with 245 individuals with AMD (34 early AMD, 168 intermediate (i) AMD, 43 late AMD), the Vision Impairment in Low Luminance (VILL) questionnaire (subscales: reading, VILL_R; mobility, VILL_M; emotional well-being, VILL_E) and visual function assessments from both eyes (best-corrected and low-luminance visual acuity, BCVA, LLVA; Moorfields acuity, MA; contrast sensitivity, CS) were included. Associations between VILL and visual function data (better and worse eyes defined based on BCVA) were investigated using age- and sex-adjusted regression models. In the overall sample, VILL_R and VILL_M were associated with all functional tests across eyes (p ≤ 0.0389), while VILL_E was associated with MA and CS (p ≤ 0.0302). Regression estimates for BCVA, LLVA, MA and CS in the better-seeing eyes were -2.70, -1.84, -1.83 and 1.08 (VILL_R); -2.71, -1.87, -1.90 and 1.88 (VILL_M), and -0.25, -0.22, -2.15 and 1.57 (VILL_E). In iAMD, CS and MA in the worse-seeing eye were associated with two VILL subscales, respectively (VILL_R and VILL_M; VILL_M and VILL_E, respectively; p ≤ 0.0395), while BCVA and LLVA in the worse-seeing eye were both associated with one VILL subscale (VILL_M; p ≤ 0.0317). CS in the better eye was associated with VILL_M (p = 0.0454). Thus, patient-reported outcomes are associated with visual function assessments in both eyes in people with AMD. Contrast vision seems particularly patient-relevant in iAMD. Our results further support the construct validity of the VILL questionnaire.

Indexed as

Macular DegenerationVision DisordersAgedAged, 80 and overContrast SensitivityCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSurveys and QuestionnairesVisual AcuityAge-related macular degenerationValidationVision-related quality of lifeVisual function

Identifiers

PMID41068150
PMCPMC12511350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.